<?xml version='1.0' encoding='utf-8'?>
<record xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
			<header>
				<identifier>oai:regsci-ojs-tamu.tdl.org:article/274</identifier>
				<datestamp>2024-02-29T04:04:11Z</datestamp>
				<setSpec>regsci:PC</setSpec>
			</header>
			<metadata>
<oai_dc:dc xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/  http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">Food and Drug Administration Oversight: Origins and Contribution to the National Covid Response: Running Title: FDA Oversight: Origins and Contributions to the Covid Response</dc:title>
	<dc:creator xml:lang="en">Grant, Bradley</dc:creator>
	<dc:creator xml:lang="en">Laposata, Michael</dc:creator>
	<dc:creator xml:lang="en">Zahner, Christopher</dc:creator>
	<dc:subject xml:lang="en">Emergency Use Authorizations (EUAs), Administrative Law, Covid-19</dc:subject>
	<dc:subject xml:lang="en">Food regulation and policy</dc:subject>
	<dc:description xml:lang="en">The Food and Drug Administration (FDA) has been a key actor in the USA’s response to the Covid-19 pandemic. The extensive use of Emergency Use Authorizations (EUAs) during the pandemic as part of its broader strategy to protect the health of the country has raised this federal agency to the public psyche. The FDA’s response has been guided by its position within the national governing framework as well as its own unique history. A review of this framework and the FDA’s history can be illuminating in understanding this agency’s response during a national crisis.</dc:description>
	<dc:publisher xml:lang="en">Office of the Texas State Chemist</dc:publisher>
	<dc:date>2024-02-28</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://regsci-ojs-tamu.tdl.org/regsci/article/view/274</dc:identifier>
	<dc:identifier>10.21423/JRS.REGSCI.121274</dc:identifier>
	<dc:source xml:lang="en">Journal of Regulatory Science; Vol. 12 No. 1 (2024)</dc:source>
	<dc:source>2377-3537</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://regsci-ojs-tamu.tdl.org/regsci/article/view/274/321</dc:relation>
	<dc:rights xml:lang="en">Copyright (c) 2024 Bradley Grant, Michael Laposata, Christopher Zahner</dc:rights>
	<dc:rights xml:lang="en">https://creativecommons.org/licenses/by-nc/4.0</dc:rights>
</oai_dc:dc>
			</metadata>
		</record>
		
